Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as part of a planned leadership transition. This decision has been made for personal reasons, as Fredrik looks to open a new chapter in life with more time for family and the opportunity to explore other professional avenues.
Fredrik has served Magle Group for more than 25 years, contributing significantly to the development and operational success of the business. His leadership and experience have been central in supporting the Group's evolution from a development-focused company into a fully integrated life sciences organisation.
Aaron Wong, Interim Chief Executive Officer, commented:
"It has been a privilege to contribute to Magle Group's journey over the years. As the company now enters its next phase, I feel the time is right for me to focus more on my family and to explore new opportunities outside the organisation. I remain fully committed to supporting a smooth transition and am confident that the business is in a strong position to continue delivering on its strategy."
The Company has a clear continuity plan in place, and the operational leadership transition will be carried out over the coming period in a structured and collaborative manner. Magle Group remains firmly focused on executing its growth strategy and operational priorities without disruption.
Contacts Aaron
Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed - a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept - an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com
Redeye is the company's Certified Adviser.
